Collins M, Ibeanu N, Grabowska W, Awwad S, Khaw P, Brocchini S
RSC Chem Biol. 2024; .
PMID: 39347456
PMC: 11427889.
DOI: 10.1039/d4cb00130c.
Zhonghua Xue Ye Xue Za Zhi. 2024; 45(7):629-636.
PMID: 39231766
PMC: 11388125.
DOI: 10.3760/cma.j.cn121090-20240528-00194.
Freitag P, Kolibius J, Wieboldt R, Weber R, Hartmann K, van Gogh M
Mol Ther Oncol. 2024; 32(3):200821.
PMID: 39021370
PMC: 11253662.
DOI: 10.1016/j.omton.2024.200821.
Lampe H, Tam L, Hansen A
Front Pharmacol. 2024; 15:1399802.
PMID: 38873417
PMC: 11169794.
DOI: 10.3389/fphar.2024.1399802.
Goebeler M, Stuhler G, Bargou R
Nat Rev Clin Oncol. 2024; 21(7):539-560.
PMID: 38822215
DOI: 10.1038/s41571-024-00905-y.
T-Cell Engagers-The Structure and Functional Principle and Application in Hematological Malignancies.
Cech P, Skorka K, Dziki L, Giannopoulos K
Cancers (Basel). 2024; 16(8).
PMID: 38672662
PMC: 11048836.
DOI: 10.3390/cancers16081580.
Combinatorially restricted computational design of protein-protein interfaces to produce IgG heterodimers.
Azzam T, Du J, Flowers M, Ali A, Hunn J, Vijayvargiya N
Sci Adv. 2024; 10(15):eadk8157.
PMID: 38598628
PMC: 11006224.
DOI: 10.1126/sciadv.adk8157.
Bi-specific autoantigen-T cell engagers as targeted immunotherapy for autoreactive B cell depletion in autoimmune diseases.
Perico L, Casiraghi F, Sonego F, Todeschini M, Corna D, Cerullo D
Front Immunol. 2024; 15:1335998.
PMID: 38469301
PMC: 10926275.
DOI: 10.3389/fimmu.2024.1335998.
Revolutionizing cancer treatment: the power of bi- and tri-specific T-cell engagers in oncolytic virotherapy.
Mehrabadi A, Tat M, Alvanegh A, Roozbahani F, Esmaeili Gouvarchin Ghaleh H
Front Immunol. 2024; 15:1343378.
PMID: 38464532
PMC: 10921556.
DOI: 10.3389/fimmu.2024.1343378.
Next generation of multispecific antibody engineering.
Keri D, Walker M, Singh I, Nishikawa K, Garces F
Antib Ther. 2024; 7(1):37-52.
PMID: 38235376
PMC: 10791046.
DOI: 10.1093/abt/tbad027.
Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression.
Ding Z, Sun S, Wang X, Yang X, Shi W, Huang X
J Hematol Oncol. 2023; 16(1):115.
PMID: 38031188
PMC: 10688028.
DOI: 10.1186/s13045-023-01507-4.
Advances in immunotherapy for triple-negative breast cancer.
Liu Y, Hu Y, Xue J, Li J, Yi J, Bu J
Mol Cancer. 2023; 22(1):145.
PMID: 37660039
PMC: 10474743.
DOI: 10.1186/s12943-023-01850-7.
A Shiga Toxin B-Subunit-Based Lectibody Boosts T Cell Cytotoxicity towards Gb3-Positive Cancer Cells.
Tomisch J, Busse V, Rosato F, Makshakova O, Salavei P, Kittel A
Cells. 2023; 12(14).
PMID: 37508560
PMC: 10378424.
DOI: 10.3390/cells12141896.
Bispecific T cell-engager targeting oncofetal chondroitin sulfate induces complete tumor regression and protective immune memory in mice.
Skeltved N, Nordmaj M, Berendtsen N, Dagil R, Stormer E, Al-Nakouzi N
J Exp Clin Cancer Res. 2023; 42(1):106.
PMID: 37118819
PMC: 10142489.
DOI: 10.1186/s13046-023-02655-8.
A high throughput bispecific antibody discovery pipeline.
Segaliny A, Jayaraman J, Chen X, Chong J, Luxon R, Fung A
Commun Biol. 2023; 6(1):380.
PMID: 37029216
PMC: 10082157.
DOI: 10.1038/s42003-023-04746-w.
Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy.
Zhang T, Lin Y, Gao Q
Cancer Biol Med. 2023; 20(3).
PMID: 36971124
PMC: 10038071.
DOI: 10.20892/j.issn.2095-3941.2023.0002.
Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer.
Simao D, Zarrabi K, Mendes J, Luz R, Garcia J, Kelly W
Cancers (Basel). 2023; 15(5).
PMID: 36900202
PMC: 10001031.
DOI: 10.3390/cancers15051412.
Palbociclib impairs the proliferative capacity of activated T cells while retaining their cytotoxic efficacy.
Arndt C, Tunger A, Wehner R, Rothe R, Kourtellari E, Luttosch S
Front Pharmacol. 2023; 14:970457.
PMID: 36817127
PMC: 9935825.
DOI: 10.3389/fphar.2023.970457.
ImmunoPET Directed to the Brain: A New Tool for Preclinical and Clinical Neuroscience.
de Lucas A, Lamminmaki U, Lopez-Picon F
Biomolecules. 2023; 13(1).
PMID: 36671549
PMC: 9855881.
DOI: 10.3390/biom13010164.
Advanced T and Natural Killer Cell Therapy for Glioblastoma.
Yoon W, Chung D
J Korean Neurosurg Soc. 2023; 66(4):356-381.
PMID: 36588388
PMC: 10323271.
DOI: 10.3340/jkns.2022.0267.